Simplex

Recce Pharmaceuticals Granted New Patent in Israel for RECCE® Anti-Infectives

Retrieved on: 
Thursday, April 4, 2024
Escherichia coli, Central Bureau, Statistics, Burn, PCT, Shingles, Biotechnology, Growth, Disease, HIV, Klebsiella pneumoniae, COVID-19, Inhalation, HCMV, ASX, RCE, Recce, Viral, Pseudomonas aeruginosa, Virus, EBV, SARS-CoV-2, Staphylococcus aureus, Gonorrhea, Cytomegalovirus, Ross River virus, Neisseria meningitidis, GDP, Urinary tract infection, Skin, Streptococcus pyogenes, Patent, Staphylococcus, Streptococcus pneumoniae, Simplex, Infection, USD, Administration, Biology, Ageing, Pharmaceutical industry

SYDNEY, Australia, April 04, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced that the State of Israel Patent Office has formally granted Recce a new family four patent (patent number: 295116), “Process for Preparation of Biologically Active Copolymer Comprising an Acrolein Derivative and a Polyalkylene Glycol Oligomer,” with expiry in 2041.

Key Points: 
  • SYDNEY, Australia, April 04, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced that the State of Israel Patent Office has formally granted Recce a new family four patent (patent number: 295116), “Process for Preparation of Biologically Active Copolymer Comprising an Acrolein Derivative and a Polyalkylene Glycol Oligomer,” with expiry in 2041.
  • “We are thrilled to have received this newly granted patent in Israel,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • Israel’s pharmaceuticals and biotechnology market has a reputation for high R&D spending and an impressive international reach, with world-class export numbers and a growing market value.
  • Other examples include influenza A, Ross River virus, and coronaviruses, including those responsible for severe acute respiratory syndrome and SARS-CoV-2 (COVID-19).

Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights

Retrieved on: 
Thursday, March 28, 2024
Research, HSV, Assembly, Biotechnology, Partnership, Viral, Doctor of Philosophy, Safety, BeiGene, Simplex, Therapy, CMO

Revenues from collaborative research were $7.2 million for the year ended December 31, 2023.

Key Points: 
  • Revenues from collaborative research were $7.2 million for the year ended December 31, 2023.
  • Research and development expenses were $48.9 million for the year ended December 31, 2023, compared to $70.0 million in 2022.
  • General and administrative expenses were $22.9 million for the year ended December 31, 2023, compared to $24.1 million in 2022.
  • The investigational products and investigational product candidates referenced here have not been approved anywhere globally, and their safety and efficacy have not been established.

Calmara, Find Love, Not STIs: Dating app users can now use AI to weed out daters with STI

Retrieved on: 
Tuesday, March 19, 2024
Health, Uncertainty, Human, Trust, SAN, Ageing, Head, Social media, Anxiety, STI, CDC, Generation Z, Safety, Simplex, Privacy, Gen, Birth control

With dating apps becoming the new norm, Calmara addresses a vital concern in the digital dating realm.

Key Points: 
  • With dating apps becoming the new norm, Calmara addresses a vital concern in the digital dating realm.
  • Dating app users have reached an astonishing 59.16 million[2], making the digital dating scene more vibrant than ever.
  • This demographic shift highlights a critical gap in sexual health awareness and screening practices, exacerbated by a declining rate of STI testing[4].
  • Calmara stands at the forefront of a cultural shift towards greater transparency and responsibility in dating.

Epiq Acquires Mainspring, Expands CLM Implementation Services

Retrieved on: 
Tuesday, November 28, 2023
Risk, Commercial, CLM, Workflow, Acquisition, Commerce, Simplex, Lawsuit, IP, Growth, Organization, Corporation, Senior, Construction

The acquisition of Mainspring Consulting Group expands Epiq’s existing Contracts Solutions business to help clients effectively manage contracts across people, processes, technology, and data.

Key Points: 
  • The acquisition of Mainspring Consulting Group expands Epiq’s existing Contracts Solutions business to help clients effectively manage contracts across people, processes, technology, and data.
  • By delivering CLM system integrations, clients get additional value from the contracting process from creation to post-signature obligations management.
  • “Mainspring’s CLM strategy, implementation, and integration services will enable our clients to get better value from their CLM technology investments.”
    The Epiq Contracts Solutions business delivers in three areas:
    Epiq Contracts Review and Analytics helps clients organize, review, and analyze their executed contracts in the context of M&A due diligence and merger integration, regulatory change, and preparing contracts for CLM implementations;
    Epiq CLM Professional Services provides advisory, CLM selection, and implementation; and,
    Epiq Counsel provides flexible legal talent for law departments facing an overwhelming volume of commercial contracts.
  • It has CLM partnerships with the leading CLM providers, including Agiloft, Conga, Ironclad, ContractPodAI, and Malbek, to name a few.

Recce Pharmaceuticals Granted New Patent in Canada for RECCE® Anti-Infectives

Retrieved on: 
Monday, November 27, 2023
Recce, Ross River virus, Simplex, ASX, Government, RCE, Klebsiella pneumoniae, PCT, Virus, Burn, Administration, Streptococcus pneumoniae, Patent, Disease, Staphylococcus aureus, Infection, Gonorrhea, Canada Revenue Agency, Inhalation, Shingles, Pseudomonas aeruginosa, Biology, COVID-19, Streptococcus pyogenes, Viral, EBV, Escherichia coli, HIV, Coronavirus, SARS-CoV-2, Cytomegalovirus, Staphylococcus, Urinary tract infection, Bacteria, Neisseria meningitidis, HCMV, Science, Skin, Pharmaceutical industry

SYDNEY, Australia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Limited (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Canadian Patent Office has formally granted Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.

Key Points: 
  • SYDNEY, Australia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Limited (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Canadian Patent Office has formally granted Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.
  • “We thank the Canadian Government for their recognition of the significant potential of Recce’s New Class of Anti-infectives,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • In July 2023, the Company received an AUD $98,428 R&D Rebate from the Canadian Government, under the Scientific Research & Experimental Development (SR&ED) Tax Incentive program.
  • The program is administered by the Canada Revenue Agency and is aimed at incentivizing businesses to conduct R&D in Canada, encouraging innovation and technological advancements.

Bioxytran Gets Broad Patent Coverage on 60+ Viruses

Retrieved on: 
Tuesday, October 24, 2023
RSV, Patent, Epstein–Barr virus, Viral, HAART, Reading, Lectin, Nipa, Hepatitis C, Measles, Protease, Pathology, HIV, Intellectual property, Virus, Cell, Research, Drug development, COVID-19, Mumps, MOA, Virology, Rubella, Simplex, Shingles, Drug resistance, Movement, Enzyme inhibitor, Plasma protein binding, DNA, Vaccine, Pharmaceutical industry, H1N1, Galectin

BOSTON, MASSACHUSETTS, Oct. 24, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19 and other viral diseases, announced that the U.S Patent and Trademark Office (USPTO) has published the Company’s patent application WO2023178228A1 Lectin-binding carbohydrates for treating viral infections. The pending patent covers broad claims about the use of hundreds of combinations of antiviral complex carbohydrate drugs to treat over 60 named viruses.

Key Points: 
  • The pending patent covers broad claims about the use of hundreds of combinations of antiviral complex carbohydrate drugs to treat over 60 named viruses.
  • This patent represents what we believe is a new direction in the evolution of antiviral therapies that originally started during the HIV epidemic.
  • This pending patent with its broad claims also shows the Company is well-positioned with respect to its intellectual property portfolio.
  • This patent covers some of the largest indications in virology and includes viruses like COVID-19, influenza, herpes, Epstein-Barr, shingles, hepatitis C, measles, mumps, and rubella.

Rocket Lab Integrating Twin Spacecraft for Mission to Mars for NASA

Retrieved on: 
Wednesday, October 18, 2023
Satellite, Technology, Aerospace, Manufacturing, Other Science, Other Manufacturing, Science, Neutron, UCB, Electron, Plasma, Security (finance), Vibration, UC, New Glenn, SMD, Moon, Climate, Science Mission Directorate, Acceleration, Rocket Lab, Multimedia, SSL, University, SIR, Rocket, Spacecraft, DSN, Space Sciences Laboratory, Lab, NASA, Annual report, Noetics, Simplex, Heliophysics, Communications satellite, Langmuir, Photon, Mars

View the full release here: https://www.businesswire.com/news/home/20231018369299/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231018369299/en/
    One of two Rocket Lab-built spacecraft for NASA and UCBSSL's ESCAPADE mission to Mars.
  • The mission will explore how the solar wind strips atmosphere away from Mars to better understand how its climate has changed over time.
  • The mission is led by the University of California, Berkeley’s (UCB) Space Sciences Laboratory (SSL) with spacecraft provided by Rocket Lab.
  • Rocket Lab’s Photon spacecraft platform has been selected to support NASA missions to the Moon and Mars, as well as the first private commercial mission to Venus.

Global Adult Vaccines Market Research Report 2023: Market to Surpass $25 Billion by 2027 - Long-term Forecasts to 2032 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 11, 2023
Health, Pharmaceutical, Measles, DPT, Research report, Hepatitis, COVID-19, Hospital, Acquisition, Food, Vaccine, Tuberculosis, Traction, Prevalence, Meningococcal vaccine, GSK plc, SARS, Infection, World Health Organization's response to the COVID-19 pandemic, Simplex, World Health Organization, Shingles, Merck, Growth, Statistics, Lonrho, Merck & Co., Tetanus, Regulation of tobacco by the U.S. Food and Drug Administration, Sanofi, Messenger, Streptococcus, Research, Themis

Various technologies are harnessed to develop these vaccines, encompassing live attenuated vaccines, inactivated viral or bacterial vaccines, toxoid vaccines, recombinant vaccines, and conjugate vaccines.

Key Points: 
  • Various technologies are harnessed to develop these vaccines, encompassing live attenuated vaccines, inactivated viral or bacterial vaccines, toxoid vaccines, recombinant vaccines, and conjugate vaccines.
  • The adult vaccines market research report is an invaluable resource, offering a wealth of statistics on the adult vaccines market, including global market size, regional distributions, insights into market competitors with their respective market shares, comprehensive segmentation of the adult vaccines market, prevailing market trends, and promising opportunities.
  • These alarming statistics underscore the pivotal role of adult vaccines in curbing the spread of contagious diseases and substantiate the burgeoning growth of the adult vaccines market.
  • The adult vaccines market encompasses the sales of mRNA vaccines and viral vector vaccines.

Texas Jury Enters a $2.45 Million Verdict Against Houston-Area Pastor for Transmitting Herpes

Retrieved on: 
Monday, October 16, 2023
Judgement, Multimedia, Cause of action, Fraud, Embarrassment, LLP, Disease, Church, Simplex, Shame, Stigma, Vertically transmitted infection, Medicine, Life, Birth control, Private investigator

Mr. West, a Houston resident, is an assistant pastor at The Church Without Walls also located in Houston.

Key Points: 
  • Mr. West, a Houston resident, is an assistant pastor at The Church Without Walls also located in Houston.
  • Houston pastor pays big price for breaking the law by transmitting herpes to woman after lying about having the disease.
  • The total judgment of $2.45 million is believed to be the largest ever awarded in Texas for a case of this nature.
  • He has achieved the largest verdict in the United States and in the states of California, Washington, and Texas.

Hey Jane Launches Comprehensive Reproductive and Sexual Health Services in the District of Columbia

Retrieved on: 
Tuesday, October 3, 2023
Technology, LGBTQ+, Pharmaceutical, Other Science, Teens, Parenting, Public Policy, Government, Retail, Insurance, Women, Professional Services, Health, Public Safety, Men, General Health, Family, Science, Other Technology, Consumer, Telemedicine, Virtual Medicine, Online Retail, Internet, State, Local, Other Health, WHNP-BC, Urinary tract infection, Patient, Bacterial vaginosis, SCOTUS, APRN, Simplex, DNP, CO, Roe v. Wade, RN, Entrepreneurship, Candidiasis, Birth control, MD

Hey Jane, the patient-centered, virtual reproductive and sexual health care clinic, announced the expansion of its services to the District of Columbia.

Key Points: 
  • Hey Jane, the patient-centered, virtual reproductive and sexual health care clinic, announced the expansion of its services to the District of Columbia.
  • "Hey Jane's entry into the District of Columbia is a significant step toward enhancing accessibility for comprehensive reproductive and sexual health care," stated Alyssa Wagner, DNP, RN, APRN, WHNP-BC, Medical Director at Hey Jane.
  • The company also recently became the first telemedicine abortion care provider to accept insurance , making reproductive and sexual health care even more financially accessible.
  • To learn more about Hey Jane's services in the District of Columbia, visit heyjane.com.